Glaukos – Epioxa sales nearly quintupled! 1 billion in revenue on the horizon for 2027
Reading Time: 3 minutes
Epioxa makes cornea therapy gentler. Quarterly sales jump from 11 to 53 million USD. iDose TR releases medication for up to three years. New study data confirm the benefits. Growth accelerates from 50 to 58%. For 2027, Glaukos expects 1 billion USD in revenue for the first time. Glaukos (GKOS) treats two eye diseases. In keratoconus, the cornea deforms, while in glaucoma (open-angle glaucoma), increased intraocular pressure can damage the optic nerve. Epioxa and iDose TR drive growth. Epioxa – gentler therapy opens new patient avenues...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
